Butyrolactone I

Butyrolactone I is an orally active and ATP-competitive inhibitor of CDK1. Butyrolactone I inhibits NF-κB, cdc2 kinase, Bax, ROS production, modulates the PERK/CHOP. Butyrolactone I mitigates heat-stress-induced Apoptosis. Butyrolactone I shows anti-inflammatory and intestinal protective activity. Butyrolactone I has antitumor effects against non-small cell lung, small cell lung, prostate cancer and leukemia. Butyrolactone I can be used in NASH research[1][2][3][4][5][6][7].

Product Specifications

CAS Number

[87414-49-1]

Product Name Alternative

Olomoucin

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Apoptosis; Bcl-2 Family; CDK; NF-κB; PERK; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/butyrolactone-i.html

Purity

99.80

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC([C@]1(C(C2=CC=C(C=C2)O)=C(C(O1)=O)O)CC3=CC(C/C=C(C)\C)=C(C=C3)O)=O

Molecular Formula

C24H24O7

Molecular Weight

424.44

Precautions

H315, H319, H335

References & Citations

[1]Nishio K, et al. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res. 1996 Nov-Dec;16 (6B) :3387-95. P|[2]Suzuki M, et al. Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines. Cancer Lett. 1999 Apr 26;138 (1-2) :121-30. |[3]Niu X, et al. Butyrolactone-I from Marine Fungal Metabolites Mitigates Heat-Stress-Induced Apoptosis in IPEC-J2 Cells and Mice Through the ROS/PERK/CHOP Signaling Pathway. Mar Drugs. 2024 Dec 17;22 (12) :564.|[4]Schimmel TG, et al. Effect of butyrolactone I on the producing fungus, Aspergillus terreus. Appl Environ Microbiol. 1998 Oct;64 (10) :3707-12.|[5]An X, et al. Isolation and identification of phase I metabolites of butyrolactone I in rats. Xenobiotica. 2017 Mar;47 (3) :236-244.|[6]Chen S, et al. Butyrolactone-I from marine fungi alleviates intestinal barrier damage caused by DSS through regulating lactobacillus johnsonii and its metabolites in the intestine of mice. J Nutr Biochem. 2025 Jan;135:109786.|[7]Tian-Qi C, et al. Butyrolactone I attenuates inflammation in murine NASH by inhibiting the NF-κB signaling pathway. Biochem Biophys Res Commun. 2022 Oct 20;626:167-174.